Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Ras signaling pathway is a critical cellular cascade that controls cell proliferation, survival, differentiation, and migration. It involves Ras proteins (HRAS, KRAS, NRAS), which act as molecular switches activated by growth factor signaling and regulated by GEFs and GAPs. Upon activation, Ras-GTP interacts with downstream effectors like RAF, PI3K, and RalGDS to initiate signaling cascades leading to cellular responses. Mutations in RAS genes, particularly KRAS, are common in cancer and lead to constitutive pathway activation.
Drugs targeting the Ras pathway aim to inhibit key proteins within the cascade, such as directly inhibiting mutant RAS proteins (e.g., KRAS G12C inhibitors), or inhibiting downstream effectors like MEK, PI3K, mTOR or RAF kinases, thereby blocking proliferative and survival signals.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ras signaling pathway.